

Jonathan J Havel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7636826/jonathan-j-havel-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21
papers

7,956
citations

15
h-index

22
g-index

22
ext. papers

10,410
ext. citations

18.5
avg, IF

6.08
L-index

#	Paper	IF	Citations
21	Qa-1 Modulates Resistance to Anti-PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing. <i>Molecular Cancer Research</i> , 2021 , 19, 1076-1084	6.6	3
20	Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. <i>JCI Insight</i> , 2020 , 5,	9.9	30
19	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. <i>Nature Medicine</i> , 2019 , 25, 767-775	50.5	149
18	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. <i>Science</i> , 2019 , 364, 485-491	33.3	228
17	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. <i>Nature Reviews Cancer</i> , 2019 , 19, 133-150	31.3	996
16	Immunogenomics 2019 , 99-110		
15	MEK Inhibitors in Lung Cancer-You Can Teach an Old Drug New Tricks. <i>Cancer Research</i> , 2019 , 79, 5699-5701	10.1	2
14	ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis. <i>Cancer Immunology Research</i> , 2018 , 6, 151-162	12.5	25
13	AKT1, LKB1, and YAP1 Revealed as MYC Interactors with NanoLuc-Based Protein-Fragment Complementation Assay. <i>Molecular Pharmacology</i> , 2017 , 91, 339-347	4.3	17
12	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. <i>Nature Communications</i> , 2017 , 8, 1197	17.4	46
11	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. <i>Cell</i> , 2017 , 171, 934-949	36.16	831
10	Enabling systematic interrogation of protein-protein interactions in live cells with a versatile ultra-high-throughput biosensor platform. <i>Journal of Molecular Cell Biology</i> , 2016 , 8, 271-81	6.3	18
9	The head and neck cancer immune landscape and its immunotherapeutic implications. <i>JCI Insight</i> , 2016 , 1, e89829	9.9	356
8	The role of neoantigens in response to immune checkpoint blockade. <i>International Immunology</i> , 2016 , 28, 411-9	4.9	88
7	Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. <i>Nature Genetics</i> , 2016 , 48, 1327-1329	36.3	84
6	Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> , 2015 , 348, 124-8	33.3	5003
5	Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway. <i>Oncogene</i> , 2015 , 34, 1487-98	9.2	35

4	High-resolution genomic analysis: the tumor-immune interface comes into focus. <i>Genome Biology</i> , 2015 , 16, 65	18.3	3
3	Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells. <i>Clinical Cancer Research</i> , 2008 , 14, 5341-7	12.9	37
2	Protein-Protein Interactions. <i>Springer Protocols</i> , 2008 , 463-494	0.3	3
1	Time-Resolved Fluorescence Resonance Energy Transfer Technologies in HTS198-214		2